Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürstenwalde – page 24

1 727 clinical trials in Fürstenwalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürstenwalde at a glance
1 727
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 727 trials in Fürstenwalde

Open in trial search

Testing bifikafusp alfa and onfekafusp alfa injections in patients with locally advanced basal cell carcinoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study of brenipatide compared to placebo for the treatment of adults with alcohol use disorder

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

A Study of Felzartamab for Kidney Transplant Patients with Late Isolated Microvascular Inflammation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Felzartamab
  • Sponsor:Biogen Idec Research Limited

A Study of Povetacicept Compared to Tacrolimus for Adults with Primary Membranous Nephropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povetacicept
  • Sponsor:Vertex Pharmaceuticals Inc.

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

HIV infection

Recruiting

A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dolutegravir Sodium
  • Sponsor:Viiv Healthcare UK Limited

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Solti Group

Pharyngitis

Recruiting

Testing benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for relief of sore throat symptoms in patients with acute pharyngitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:2,4 dichlorobenzyl alcohol
  • Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürstenwalde

What the registry says about research in the country

01 Respiratory Tract Diseases

Clinical research in Fürstenwalde Spree is focused on respiratory tract diseases, with all active studies centered on asthma and its more severe forms. These trials are looking at new treatment options, safety, and signs of better disease control for people with difficult-to-manage asthma.

  • Asthma and uncontrolled asthma
  • Severe eosinophilic asthma and eosinophilic phenotype
  • Moderate to severe controlled asthma under current guideline-based care
  • Testing new therapies and comparing them with existing treatments

The research includes studies of inhaled and biologic approaches, with an emphasis on improving symptom control, evaluating long-term safety, and measuring airway inflammation markers.

02 Asthma Treatment Safety and Tolerability

One part of the local trial landscape examines how well new asthma treatments are tolerated, especially in people already living with persistent disease. These studies help determine whether emerging options can offer benefits while remaining safe for everyday use.

  • Asthma treatment safety
  • Comparing different inhaled therapy formulations
  • Assessing long-term safety in ongoing care

This work supports clearer decisions about whether new therapies can be used comfortably and reliably in routine respiratory medicine.

03 Severe Eosinophilic Asthma

Several studies are dedicated to severe eosinophilic asthma, a more advanced form of asthma linked to ongoing inflammation. The goal is to see whether newer biologic treatments can improve control for patients who have already responded to specialized care.

  • Severe eosinophilic asthma
  • Evaluating biologic treatments for better disease control
  • Studying patients who benefited from prior anti-IL-5 or anti-IL-5R therapy

These trials aim to refine treatment choices for people with persistent eosinophilic airway inflammation and ongoing symptoms.

04 Biologic Therapies for Asthma

The research portfolio also includes studies of targeted biologic therapies for asthma, especially for patients with frequent symptoms or severe inflammatory disease. These trials are designed to test whether newer medicines can offer stronger and longer-lasting benefit than current options.

  • Biologic treatment strategies
  • Severe asthma management
  • Comparing new targeted therapies with established care

This area highlights a broader move toward more precise respiratory research that matches therapy to the underlying disease pattern.

05 Inflammation Markers and Asthma Control

Another important focus is the study of markers that reflect airway inflammation in asthma. By observing changes such as FeNO, researchers can better understand how well a treatment is affecting the underlying disease process.

  • Fraction of exhaled nitric oxide (FeNO)
  • Uncontrolled asthma
  • Evaluating whether new therapy can reduce airway inflammation

This kind of research helps improve both diagnosis and treatment monitoring in respiratory tract disease care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.